Results 51 to 60 of about 227,142 (341)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Journal for ImmunoTherapy of Cancer
Background TG6050 was designed as an improved oncolytic vector, combining the intrinsic properties of vaccinia virus to selectively replicate in tumors with the tumor-restricted expression of recombinant immune effectors to modify the tumor immune ...
Laetitia Fend, Eric Quemeneur, Jean-Baptiste Marchand, Nathalie Silvestre, Johann Foloppe, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fadi Azar, Christelle Demeusoit, Clémentine Spring-Giusti   +10 more
doaj   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors

Molecular Therapy: Oncolytics, 2023
TG6002 is an oncolytic vaccinia virus expressing FCU1 protein, which converts 5-fluorocytosine into 5-fluorouracil. The study objectives were to assess tolerance, viral replication, 5-fluorouracil synthesis, and tumor microenvironment modifications to ...
Jérémy Béguin, Eve Laloy, Sandrine Cochin, Murielle Gantzer, Isabelle Farine, Christelle Pichon, Baptiste Moreau, Johann Foloppe, Jean-Marc Balloul, Christelle Machon, Jérôme Guitton, Dominique Tierny, Bernard Klonjkowski, Eric Quéméneur, Christelle Maurey, Philippe Erbs   +15 more
doaj  

Nucleic Acid-Based Approaches for Tumor Therapy

Cells, 2020
Within the last decade, the introduction of checkpoint inhibitors proposed to boost the patients’ anti-tumor immune response has proven the efficacy of immunotherapeutic approaches for tumor therapy.
Simone Hager, Frederic Julien Fittler, Ernst Wagner, Matthias Bros   +3 more
doaj   +1 more source

Neuronal Transgene Expression in Dominant-Negative SNARE Mice

Journal of Neuroscience, 2014
Experimental advances in the study of neuroglia signaling have been greatly accelerated by the generation of transgenic mouse models. In particular, an elegant manipulation that interferes with astrocyte vesicular release of gliotransmitters via ...
T. Fujita, Michael J. Chen, Baoman Li, N. A. Smith, Weiguo Peng, Wei Sun, Michael J Toner, Benjamin T. Kress, Linhui Wang, A. Benraiss, T. Takano, Su Wang, M. Nedergaard   +12 more
semanticscholar   +1 more source

Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors

Molecular Oncology, EarlyView.
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley   +1 more source

Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons

Molecular Brain, 2014
Adeno-associated virus (AAV) vectors can deliver transgenes to diverse cell types and are therefore useful for basic research and gene therapy. Although AAV has many advantages over other viral vectors, its relatively small packaging capacity limits its ...
Jun-Hyeok Choi, Nam-Kyung Yu, Gi-Chul Baek, Joseph Bakes, Daekwan Seo, Hye Jin Nam, S. H. Baek, C. Lim, Yong-Seok Lee, B. Kaang   +9 more
semanticscholar   +1 more source

Alleviation of Aging‐Related Hallmarks in a Mouse Model of Progeria via a Nanoparticle‐Based Artificial Transcription Factor

Advanced Functional Materials, EarlyView.
Oct4‐nanoscript, a biomimetic nanoparticle‐based artificial transcription factor, precisely regulates cellular rejuvenation by activating Oct4 target genes, restoring epigenetic marks, and reducing DNA damage. In a progeria model, it effectively rescued aging‐associated pathologies and extended lifespan.
Hongwon Kim, Junyeop Kim, Euiyeon Lee, Brandon Conklin, Yannan Hou, Sumin Kim, Yerim Hwang, Ki‐Bum Lee, Jongpil Kim   +8 more
wiley   +1 more source